EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy, safety, and economic evaluation of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: Protocol for a randomized, double-blind, placebo-controlled, parallel, multicenter, investigator-initiated clinical trial

Yee Ran Lyu iD, O-Jin Kwon, Ae-Ran Kim, Min Ji Kim, Yoon Jae Lee, Kwan-Il Kim, Jae-Woo Park, Seok-Jae Ko iD, Yang-Chun Park, Jun-Yong Choi, Tae-Yong Park, Jun-Hwan Lee iD und 1 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0325786 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS One, 2025. Verfasst von Yee Ran Lyu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Korean Medicine Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Cough, Drugs, Chinese Herbal, Gastroesophageal Reflux. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gastroesophageal reflux-induced chronic cough (GERC) is a common extraesophageal manifestation of gastroesophageal reflux disease (GERD). However, the mechanisms underlying GERC remain unclear, and current treatments with anti-reflux drugs do not provide significant benefits in the management of GERC. Therefore, safe and effective drugs to treat GERC are urgently needed. Methods and analysis We designed a randomized, double-blind, placebo-controlled, parallel, multi-center, investigator-initiated clinical trial to assess the efficacy, safety, and economics of combined Ojeok-san (OJS) and Saengmaek-san (SMS) in treating GERC. Our trial will be conducted in five hospitals in Korea, and a total of 138 participants will be enrolled, equally divided between the OJS plus SMS and placebo groups. All participants will be instructed to receive OJS plus SMS or a placebo for 6 weeks and visit hospitals every 2 weeks until week 8 to evaluate their efficacy or safety outcomes. For efficacy outcomes, the cough diary score, cough VAS, Leicester Cough Questionnaire, Gastroesophageal Reflux Disease Questionnaire, Hull Airway Reflux Questionnaire, and 5-level EuroQol 5-dimensional Questionnaire will be evaluated to observe symptoms of cough and GERD, as well as the quality of life in patients with GERC. Pattern identification for the Chronic Cough Questionnaire and gastroesophageal reflux disease will be measured as an additional exploratory outcome. Safety will be assessed in terms of laboratory tests, vital signs, and adverse events; economic evaluation will be simultaneously conducted through the healthcare system and societal perspectives by estimating cost-utility and cost-effectiveness.

Conclusion

Our study proposes a combination of OJS and SMS to manage the symptoms of GERC as a new insight and this study results will provide scientific evidence for the use of OJS plus SMS in the treatment of GERC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoughDrugs, Chinese HerbalGastroesophageal RefluxAdultFemaleHumansMaleMiddle AgedChronic CoughChronic DiseaseDouble-Blind MethodTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as Topic

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Korean Medicine Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
  • Clinical Medicine Division, R&D Strategy Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
  • Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, Republic of Korea.
  • Division of Allergy, Immune and Respiratory System, Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Gastroenterology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
  • Division of Respiratory Medicine, Department of Internal Medicine, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.

ORCID-Profile: Yee Ran Lyu, Seok-Jae Ko, Jun-Hwan Lee

Förderung

  • Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Lyu, Y. R., Kwon, O. J., Kim, A. R., Kim, M. J., Lee, Y. J., Kim, K. I., Park, J. W., Ko, S. J., Park, Y. C., Choi, J. Y., Park, T. Y., Lee, J. H., & Lee, B. J. (2025). Efficacy, safety, and economic evaluation of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: Protocol for a randomized, double-blind, placebo-controlled, parallel, multicenter, investigator-initiated clinical trial. PLOS One. https://doi.org/10.1371/journal.pone.0325786

Vancouver

Lyu YR, Kwon OJ, Kim AR, Kim MJ, Lee YJ, Kim KI, et al. Efficacy, safety, and economic evaluation of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: Protocol for a randomized, double-blind, placebo-controlled, parallel, multicenter, investigator-initiated clinical trial. PLOS One. 2025. doi:10.1371/journal.pone.0325786

BibTeX
@article{Lyu2025,
  author = {Lyu, Yee Ran and Kwon, O-Jin and Kim, Ae-Ran and Kim, Min Ji and Lee, Yoon Jae and Kim, Kwan-Il and Park, Jae-Woo and Ko, Seok-Jae and Park, Yang-Chun and Choi, Jun-Yong and Park, Tae-Yong and Lee, Jun-Hwan and Lee, Beom-Joon},
  title = {Efficacy, safety, and economic evaluation of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: Protocol for a randomized, double-blind, placebo-controlled, parallel, multicenter, investigator-initiated clinical trial},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325786}
}
Kostenlos starten →